中國生物科技服務(08037.HK)一季度由虧轉盈2723.9萬港元 將盡快開展CAR-T產品一期臨牀試驗
格隆匯5月12日丨中國生物科技服務(08037.HK)公吿，截至2021年3月31日止3個月，公司營業額1.54億港元，同比大幅增長約11.14倍；毛利7522萬港元，同比大增24倍；期間溢利2723.9萬港元，上年同期虧損2470.8萬港元。
由於COVID-19持續出現，以及制訂規例規定高風險羣組及高危羣組須進行強制檢測，對COVID-19檢測服務的需求仍高。為把握需求轉為以COVID-19測試服務為主的市場份額，集團已經在香港設立一間實驗室，為私家診所、公司及政府客户以及個人提供COVID-19檢測服務。此外，集團在香港國際機場設立移動實驗室，為到港旅客提供COVID-19檢測服務。因此，於2021年第一季度期間，透過策略性發展及市場推廣及宣傳活動，來自提供醫學實驗室檢測服務及健康檢查服務分部的收入出現大幅增加。
取得溢利淨額主要是由於以下各項所致：(i)香港於2020年11月出現第四波新冠肺炎疫情，導致對COVID-19檢測服務的需求大幅增加；及(ii)透過策略性發展及市場推廣及宣傳活動，以致提供醫學實驗室檢測服務及健康檢查服務分部的收入及毛利出現強勁增長。
2021年第一季度期間的毛利率約為48.79%，較2020年第一季度期間的毛利率約23.59%上升約25.20個百分點。毛利率上升乃由於提供醫學實驗室檢測服務及健康檢查服務分部的營業額大幅上升。
公司表示，疫情的持續將為集團的新冠病毒檢測業務以及機場檢測帶來收入，隨着疫苗的逐漸普及接種，集團將對檢測業務進行調整以把握新的機遇。集團由於就疫症大流行推出更成熟的控制措施而有望開展更多的國際合作，包括免疫細胞藥物研發方面的海外註冊以及海外項目的引進等。
集團將迎接挑戰，把握機遇，積極探索將檢測業務進行多元化轉型；儘快開展已經獲得臨牀批件的CAR-T產品的一期臨牀試驗，同時推進針對實體瘤的CAR-T產品以及通用CAR-T產品的研發和臨牀批件申報準備工作；引進具有潛力的海外項目，深化在大灣區的醫療健康產業佈局，致力於成為國際先進的生物醫療創新平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
